SQNM » Topics » Research and Development

These excerpts taken from the SQNM 10-K filed Mar 12, 2009.

Research and Development

 

We believe that investment in research and development is essential to establishing a long-term competitive position as a provider of genetic analysis tools and as a provider or an enabler of diagnostic tests. Our research and development expenses for the years ended December 31, 2008, 2007, and 2006, were $27.5 million, $14.4 million, and $11.9 million, respectively.

 

During 2008 we conducted most of our research and development activities at our facilities in the United States. Our research and development is augmented by advisory and collaborative relationships with others.

 

Our research and development efforts are primarily focused on expanding the applications for our MassARRAY technology, research and development of diagnostic assays, and research and development of other prenatal diagnostic methods and technologies that are relevant to diagnosing disorders or conditions such as thalassemias, cardiac disorders, congenital disorders and autism, as well as for oncology and infectious diseases and certain other diseases, including the sample preparation step of enriching fetal nucleic acid for subsequent analysis.

 

11


Table of Contents

Research and Development

 

STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%">We believe that investment in research and development is essential to establishing a long-term competitive position as a provider of genetic analysis
tools and as a provider or an enabler of diagnostic tests. Our research and development expenses for the years ended December 31, 2008, 2007, and 2006, were $27.5 million, $14.4 million, and $11.9 million, respectively.

STYLE="margin-top:0px;margin-bottom:0px"> 

During 2008 we conducted most of our research and development activities at
our facilities in the United States. Our research and development is augmented by advisory and collaborative relationships with others.

 

STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%">Our research and development efforts are primarily focused on expanding the applications for our MassARRAY technology, research and development of
diagnostic assays, and research and development of other prenatal diagnostic methods and technologies that are relevant to diagnosing disorders or conditions such as thalassemias, cardiac disorders, congenital disorders and autism, as well as for
oncology and infectious diseases and certain other diseases, including the sample preparation step of enriching fetal nucleic acid for subsequent analysis.

 


11







Table of Contents


This excerpt taken from the SQNM 10-K filed Mar 17, 2008.

Research and Development

 

We believe that investment in research and development is essential to establishing a long-term competitive position as a provider of genetic analysis tools and as a provider or an enabler of diagnostic tests. Our research and development expenses for the years ended December 31, 2007, 2006, and 2005, were $14.4 million, $11.9 million, $11.9 million, respectively.

 

During 2007 we conducted most of our research and development activities at our facilities in the United States. Our research and development is augmented by advisory and collaborative relationships with others.

 

Our research and development efforts are primarily focused on expanding the applications for our MassARRAY technology, research and development of diagnostic assays, and research and development of prenatal diagnostic methods and technologies, including the sample preparation step of enriching fetal nucleic acid for subsequent analysis.

 

This excerpt taken from the SQNM 10-K filed Mar 30, 2007.

Research and Development

 

We believe that investment in research and development is essential to establishing a long-term competitive position as a provider of genetic analysis tools and as a provider or an enabler of diagnostic tests. Our research and development expenses for the years ended December 31, 2006, 2005, and 2004, were $11.9 million, $11.9 million, and $18.6 million, respectively.

 

During 2006 we conducted most of our research and development activities at our facilities in the United States. Our research and development is augmented by advisory and collaborative relationships with others.

 

Our research and development efforts are primarily focused on expanding the applications for our MassARRAY technology, research and development of diagnostic assays, and research and development of prenatal diagnostic methods and technologies, including the sample preparation step of enriching fetal nucleic acid for subsequent analysis.

 

This excerpt taken from the SQNM 10-K filed Mar 31, 2006.

Research and Development

 

We believe that investment in research and development is essential to establishing a long-term competitive position as a provider of genetic analysis tools and diagnostic tests. Our research and development expenses for the years ended December 31, 2005, 2004, and 2003, were $11.8 million, $18.6 million, and $23.3 million, respectively.

 

8


Table of Contents

During 2005 we conducted most of our research and development activities at our facilities in the United States. Our research and development is augmented by advisory and collaborative relationships with others.

 

Our research and development efforts are primarily focused on expanding the applications for our MassARRAY technology and development for diagnostic applications.

 

This excerpt taken from the SQNM 10-K filed Mar 16, 2005.

Research and Development

 

We believe that substantial investment in research and development is essential to establishing a long-term competitive position as a provider of genetic analysis tools and diagnostic content. Our research and development expenses for the years ended December 31, 2004, 2003, and 2002, were $18.6 million, $23.3 million, and $30.7 million, respectively.

 

During 2004 we conducted most of our research and development activities at our facilities in the United States. Our research and development is augmented by advisory and collaborative relationships with others.

 

Our research efforts are primarily focused on expanding the applications for our MassARRAY technology, developing new technologies, and development for diagnostic applications.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki